【益佰是哪个国家的品牌？】

外推网助力益佰品牌出海！将品牌入驻外推网，定制益佰品牌推广信息，可以显著提高益佰产品曝光，简直是跨境电商爆单神器！目前仅需1000元/年哦~

英文翻译：Guizhou Yibai Pharmaceutical Co., Ltd. is a well-known pharmaceutical brand, mainly including Keke family series / Aidi injection / gingko Damo injection / lobaplatin for injection / qianliehuangrentong granules and other products. Guizhou Yibai Pharmaceutical Co., Ltd. is a high-tech enterprise integrating research, development, production and sales of new drugs Sales as one of the enterprises. The company was founded on June 12, 1995, completed the share-holding transformation in November 2000, and successfully listed on the Shanghai Stock Exchange in March 2004 (Stock Code: 600594). The company covers an area of 134398 square meters, and has built 43200 square meters of production plant in line with the GMP. At present, it has 3 production bases in the province and 4 production bases outside the province. There are 49 products and 9 injection production lines including small injection, freeze-dried powder injection and large infusion. Equipped with internationally advanced production equipment. At present, the company's main products include Keke family series, Aidi injection, gingko Damo injection, lobaplatin for injection, compound cantharis capsule, Liqihuoxue dropping pill, qianliehuangaotong granules and many other superior varieties. Among these products, Aidi injection and cantharis capsule are two-phase anti-tumor drugs, among which the research of Aidi injection has reached the level of gene; The fourth generation of Ginkgo biloba preparation, Ginkgo biloba Damo injection, is an effective drug for the treatment of heart, cerebrovascular and peripheral circulation disorders. Its appearance has brought good news to the vast number of patients with cardiovascular and cerebrovascular diseases. Lotplatin for injection is a new drug of the state. The third generation of platinum antitumor drugs, compared with other platinum, has lower toxicity and less drug resistance. Liqihuoxue dropping pill is the exclusive original vaccine drug, which is the first-line drug for the treatment of cardiovascular diseases and has great market potential. The company has always attached great importance to the protection of intellectual property. In 2004, it established a special intellectual property department, and applied for patent protection, focused on the development of core technology, and improved the ability of independent innovation of enterprises. Among them, the company has applied for 199 invention patents and authorized 115; applied for 82 appearance patents and authorized 76. 94 pre clinical studies and registration applications were completed, 7 clinical studies were carried out, and 27 production approvals were obtained.

本文链接： https://www.waitui.com/brand/27dbf8bc8.html 联系电话：请联系客服添加 联系邮箱：请联系客服添加